Proteomics Analysis of Trastuzumab Toxicity in the H9c2 Cardiomyoblast Cell Line and its Inhibition by Carvedilol

Author(s): Elham Beiranvand, Fatemeh Torkashvand, Seyed N. Ostad, Mehdi Mirzaie, Esmat M. Ardakani, Fatemeh Zandi, Soroush Sardari, Ghasem H. Salekdeh, Mohammad A. Shokrgozar, Behrouz Vaziri*

Journal Name: Current Pharmaceutical Biotechnology

Volume 21 , Issue 13 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Objective: Heart dysfunctions are the major complications of trastuzumab in patients with Human Epidermal growth factor Receptor-2 (HER2)-positive breast cancers.

Methods: In this study, the cytotoxicity of trastuzumab on H9c2 cardiomyoblasts was demonstrated, and the proteome changes of cells were investigated by a tandem mass tagging quantitative approach. The Differentially Abundant Proteins (DAPs) were identified and functionally enriched.

Results: We determined that carvedilol, a non-selective beta-blocker, could effectively inhibit trastuzumab toxicity when administrated in a proper dose and at the same time. The proteomics analysis of carvedilol co-treated cardiomyoblasts showed complete or partial reversion in expressional levels of trastuzumab-induced DAPs.

Conclusion: Downregulation of proteins involved in the translation biological process is one of the most important changes induced by trastuzumab and reversed by carvedilol. These findings provide novel insights to develop new strategies for the cardiotoxicity of trastuzumab.

Keywords: Cardiotoxicity, trastuzumab, proteomics, carvedilol, cardiomyoblast, translation.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 13
Year: 2020
Published on: 28 November, 2020
Page: [1377 - 1385]
Pages: 9
DOI: 10.2174/1389201021666200515135548
Price: $65

Article Metrics

PDF: 30